Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Montano

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
The American Journal of Gastroenterology|June 27, 2019
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary CholangitisCumali Efe, Koray Taşçilar, Ida Henriksson, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
Journal of Hepatology|April 11, 2020
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitisChristophe Corpechot, Olivier Chazouillères, Pierre Belnou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
Journal of Autoimmunity|September 11, 2022
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisCumali Efe, Koray Taşçılar, Alessio Gerussi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 10, 2022
Impact on follow-up strategies in patients with primary sclerosing cholangitisAnnika Bergquist, Tobias J Weismüller, Cynthia Levy, et al.
Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.
Journal of Hepatology|July 1, 2022
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitisChristophe Corpechot, Fabrice Carrat, Farid Gaouar, et al.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
Hepatology (Baltimore, Md.)|May 14, 2022
Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcomeCumali Efe, Anand V Kulkarni, Benedetta Terziroli Beretta-Piccoli, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
The American Journal of Gastroenterology|June 27, 2019
Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary CholangitisCumali Efe, Koray Taşçilar, Ida Henriksson, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
Journal of Hepatology|April 11, 2020
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitisChristophe Corpechot, Olivier Chazouillères, Pierre Belnou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 18, 2019
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel DiseasesKate D Lynch, Roger W Chapman, Satish Keshav, et al.
Journal of Autoimmunity|September 11, 2022
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitisCumali Efe, Koray Taşçılar, Alessio Gerussi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 10, 2022
Impact on follow-up strategies in patients with primary sclerosing cholangitisAnnika Bergquist, Tobias J Weismüller, Cynthia Levy, et al.
Journal of Hepatology|May 11, 2025
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trialCynthia Levy, George F Abouda, Bahri M Bilir, et al.
Journal of Hepatology|July 1, 2022
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitisChristophe Corpechot, Fabrice Carrat, Farid Gaouar, et al.
JHEP Reports : Innovation in Hepatology|October 9, 2024
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitisSurain B Roberts, Woo Jin Choi, Lawrence Worobetz, et al.
Hepatology (Baltimore, Md.)|May 14, 2022
Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcomeCumali Efe, Anand V Kulkarni, Benedetta Terziroli Beretta-Piccoli, et al.
Pageof 19